IP Library › Granted Patent US 10,702,509
Granted Patent B2
US 10,702,509 · App. 16/014,290 · Granted Jul 7, 2020

Animal treatments

Inventors: David Rock (Hillsborough, NJ); Mark Ridall (Princeton, NJ)
Assignee: NewMarket Pharmaceuticals LLC
A61K31/4439A61K9/0053A61K31/135A61K31/137A61K31/155A61K31/341A61K31/403A61K31/4164A61K31/4174A61K31/44A61K31/5415A61K31/635A61K31/7048C07D307/52C07D401/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,702,509
App. No.
16/014,290
Granted
Jul 7, 2020
Kind
B2
Abstract

Compositions and methods for the treatment and control of various conditions in an animal which comprises administering to said animal an effective amount of a immediate release composition of about 0.5% to 50% wt/wt of active ingredient together with excipients to a total of about 100%, wherein said composition dissolves in a relatively short period of time, e.g., 75 seconds or less, 5 seconds or less, or 3 seconds or less, upon administration to said animal.

Claims (16)

1. A method of treating parasites, summer sores, or dermatitis in an animal of need thereof, the method comprising:

determining a dose of ivermectin required; and

administering orally to a pre-gastric mucosal cell of the animal a Direct Systemic Introduction (DSI) composition comprising ivermectin,

wherein the DSI composition in the animal's oral cavity is dissolved in less than about 75 seconds, and

wherein measuring of greater than 50% of the administered ivermectin is absorbed into the animal's circulatory system via the pre-gastric mucosal cells lining the animal's alimentary canal prior to the animal's secretory stomach.

2. The method according to claim 1 , wherein the DSI composition is dissolved in less than about 30 seconds.

3. The method according to claim 1 , wherein the DSI composition is dissolved in less than about 5 seconds.

4. The method according to claim 1 , wherein the ivermectin is present in the composition in an amount ranging from about 0.5% to about 50% by weight of the overall composition.

5. The method according to claim 1 , wherein the DSI composition comprises gelatin.

6. The method according to claim 1 , wherein the ivermectin is in the form of a free base;

a water soluble salt; or an isolated single enantiomer or mixture thereof.

7. The method according to claim 1 , wherein the animal is human.

8. The method according to claim 1 , wherein the animal is an equine.

9. The method according to claim 1 , wherein the DSI composition comprises at least one excipient.

10. The method according to claim 1 , wherein the DSI composition is administered to the oral cavity of the animal.

11. The method according to claim 1 , wherein the DSI composition provides an immediate release of ivermectin.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2019
From: ROCK, DAVID; RIDALL, MARK
To: NEWMARKET PHARMACEUTICALS LLC
Reel/Frame 050713/0121 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2019
From: RIDALL, MARK
To: NEWMARKET PHARMACEUTICALS LLC
Reel/Frame 050714/0108 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PRTY TO NEWMARKET PHARMACEUTICALS LLC AND RECEIVING PRTY TO VETBRIDGE PRODUCT DEVELOPMENT SUBSIDIARY I (NM-OMP), LLC PREVIOUSLY RECORDED ON REEL 047254 FRAME 0898. ASSIGNOR(S) HEREBY CONFIRMS THE THE EXCLUSIVE DISTRIBUTION AND LICENSE AGREEMENT.. Recorded Jul 26, 2019
From: NEWMARKET PHARMACEUTICALS LLC
To: VETBRIDGE PRODUCT DEVELOPMENT SUBSIDIARY I (NM-OMP), LLC
Reel/Frame 049888/0847 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT THE PATENT NO: PREVIOUSLY RECORDED AT REEL: 046924 FRAME: 0600. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Feb 28, 2019
From: NEWMARKET PHARMACEUTICALS LLC
To: RIDALL, MARK
Reel/Frame 048467/0351 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2018
From: NEWMARKET PHARMACEUTICALS LLC
To: RIDALL, MARK
Reel/Frame 046924/0600 →
EXCLUSIVE DISTRIBUTION AND LICENSE AGREEMENT Recorded Jul 17, 2018
From: VETBRIDGE PRODUCT DEVELOPMENT SUBSIDIARY
To: NEWMARKET PHARMACEUTICALS LLC
Reel/Frame 047254/0898 →
Continuity (4)
Continuation 14275019 · May 12, 2014
Continuation 13343692 · Jan 4, 2012
Provisional Application 61437763 · Jan 31, 2011
Related Publication 20180360816A1 · Dec 20, 2018
Cited By (2)
US 12,496,295 US 12,653,812